Form 10-Q TEVA PHARMACEUTICAL INDU For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Teva Pharma (TEVA) PT Raised to $18 at BofA Securities
May 9, 2024 6:16 AM EDTBofA Securities analyst Jason Gerberry raised the price target on Teva Pharma (NYSE: TEVA) to $18.00 (from $16.00) while maintaining a Buy rating.
The analyst comments "We raise our TEVA PO to $18 (from $16) following positive Phase 3 SOLARIS trial
update for the Olanzapine LAI [long-acting... More
